Treatment with SC vs IV tocilizumab led to higher long-term remission rates in GCA-associated aortitis, though imaging and glucocorticoid-sparing outcomes were similar.

Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...

The TULIP-SC trial evaluated the efficacy and safety of the subcutaneous administration of SAPHNELO compared to placebo in participants with moderately to severely active, autoantibody-positive SLE, ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous administration of a breast cancer therapy significantly decreased treatment time compared with IV ...

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...

ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous ...

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA. HealthDay News — About one-third of health care professionals who are aware of ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the ...